Tailoring the treatment of premenopausal patients with breast cancer.

COI Statement

EM reports travel grants from Roche, Novartis, Pfizer, Gilead Sciences, Lilly, AstraZeneca, and Pierre Fabre and participation on a Data and Safety Monitoring Board or Advisory Board for Eisai, Exact Sciences, MSD Oncology, Daiichi-Sankyo/AstraZeneca, Pfizer, and Seagen. CV declares no competing interests.